Lilly glucagon

DRUG4 trials

Sponsors

Steven J. Russell, MD, PhD, Biodel, Massachusetts General Hospital, Xeris Pharmaceuticals

Conditions

Diabetes Mellitus Type 1HypoglycemiaInsulin HypoglycemiaSevere HypoglycemiaType 1 DiabetesType 1 Diabetes Mellitus

Phase 1

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

CompletedNCT02403648

BiodelHypoglycemia

Start: 2014-11-30Updated: 2016-01-15

Phase 2

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

CompletedNCT02018627

Steven J. Russell, MD, PhDType 1 Diabetes

Start: 2014-04-30End: 2018-08-02Updated: 2019-10-08

Phase 3

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

CompletedNCT03439072

Xeris PharmaceuticalsInsulin Hypoglycemia, Severe Hypoglycemia, Type 1 Diabetes Mellitus

Start: 2018-01-23End: 2018-05-03Updated: 2020-02-17

Unknown Phase

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

TerminatedNCT02701257

Massachusetts General HospitalDiabetes Mellitus Type 1

Start: 2016-03-31End: 2018-05-31Updated: 2019-11-18

Related Papers

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies

BMJ Open Diabetes Research & Care2021-10-0121 citations